share_log

HC Wainwright & Co. Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $600

HC Wainwright & Co. Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $600

HC Wainwright & Co. 维持对福泰制药的买入评级,将目标股价上调至600美元。
Benzinga ·  08/05 15:29  · 评级/大行评级

HC Wainwright & Co. analyst Andrew Fein maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $500 to $600.

HC Wainwright公司分析师Andrew Fein认为福泰制药(纳斯达克: VRTX)值得买入且将价格目标从$500提高至$600。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发